Table 4.
Comparison of the pathological results between the Han (n = 287) and Uygur group (n = 264) of BC patients
| Variables | Han (n (%)) | Uygur (n (%)) | X 2 (df)/Z | P-value |
|---|---|---|---|---|
| Pathological composition | 6.665 | 0.010 | ||
| Single | 212 (73.9) | 219 (83) | ||
| IDC | 203 (95.8) | 193 (88.1) | 8.76 | 0.013 |
| ILC | 5 (2.4) | 11 (5) | ||
| MC | 4 (1.9) | 15 (6.8) | ||
| Multiple | 75 (26.1) | 45 (17) | ||
| IDC + ILC | 30 (40) | 24 (53.3) | 4.238 | 0.516 |
| IDC + tubular adenocarcinoma | 12 (16) | 3 (6.7) | ||
| IDC + medullary carcinoma | 6 (8) | 4 (8.9) | ||
| IDC + myxoadenocarcinoma | 4 (5.3) | 3 (6.7) | ||
| IDC + apocrine carcinoma | 9 (12) | 6 (13.3) | ||
| IDC + CIS | 14 (18.7) | 5 (11.1) | ||
| Tumor size | 18.746 | < 0.001 | ||
| T1 | 128 (44.6) | 74 (28) | ||
| T2 | 145 (50.5) | 167 (63.3) | ||
| T3 | 10 (3.5) | 20 (7.6) | ||
| T4 | 4 (1.4) | 3 (1.1) | ||
| Metastatic LN | 4.275* | < 0.001 | ||
| 0 | 153 (55) | 92 (36.4) | ||
| 1~3 | 54 (19.4) | 68 (26.9) | ||
| 4~9 | 42 (15.1) | 43 (17) | ||
| ≥ 10 | 29 (10.4) | 50 (19.8) | ||
| Resected LN | 4.669* | < 0.001 | ||
| 1~9 | 36 (12.9) | 10 (4) | ||
| 10~19 | 203 (73) | 176 (69.6) | ||
| ≥ 20 | 39 (14) | 67 (26.5) | ||
| Pathological Staging | 21.462 | < 0.001 | ||
| I | 84 (29.3) | 38 (14.4) | ||
| II | 125 (43.6) | 118 (44.7) | ||
| III | 78 (27.2) | 108 (40.9) | ||
| Molecular subtypes | 2.527 | 0.47 | ||
| Luminal A | 179 (62.4) | 151 (57.2) | ||
| Luminal B | 31 (10.8) | 34 (12.9) | ||
| Her-2 positive | 27 (9.4) | 22 (8.3) | ||
| Tripple negative | 50 (17.4) | 57 (21.6) | ||
| Ki-67 | 0.916 | 0.339 | ||
| - | 81 (28.2) | 65 (24.6) | ||
| + | 206 (71.8) | 199 (75.4) | ||
| Her-2 | 0.084 | 0.772 | ||
| - | 229 (79.8) | 208 (78.8) | ||
| + | 58 (20.2) | 56 (21.2) | ||
| Nm23 | 14.532 | < 0.001 | ||
| - | 74 (25.8) | 34 (12.9) | ||
| + | 213 (74.2) | 230 (87.1) | ||
*
The results for the “z” test;
Abbreviations: BC-breast cancer; IDC-invasive ductal carcinoma; ILC-invasive lobular carcinoma; MC-medullary carcinoma; CIS- carcinoma in situ; LN-lymph node.